This article is more than 5 years old. Information may no longer be current.
First patient enrolled in phase 2/3 study of Alzheimer's disease treatment
Click Here to Manage Email Alerts
The first patient has been enrolled into a phase 2/3 study of a potential treatment for early Alzheimer’s disease, according to a press release from Eli Lilly and AstraZeneca.
The safety and efficacy of the oral beta secretase cleaving enzyme inhibitor, AZD3293, also known as LY3314814, will be examined in comparison with placebo in the AMARANTH study. According to the press release, the study has a 2-year treatment period and aims to enroll more than 1,500 patients in 15 countries.
In phase 1 studies, AZD3293/LY3314814 was associated with lower levels of amyloid-beta in the cerebrospinal fluid of patients with Alzheimer’s disease and healthy volunteers, according to the press release. Beta secretase cleaving enzyme is associated with amyloid-beta development, therefore its inhibition is expected to slow the progression of disease.
Earlier this year Eli Lilly and AstraZeneca announced a partnership for the development and commercialization of AZD3293/LY3314814. According to their agreement, clinical development will be led by Eli Lilly in collaboration with researchers from AstraZeneca’s Neuroscience Innovative Medicines Unit, and AstraZeneca will be in charge of manufacturing. The costs of development and commercialization, as well as net global revenues, will be shared among the two companies.